Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

NCT06993844 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
Advanced Breast Cancer

Interventions

DRUG: ETX-636 dose escalation
DRUG: ETX-636 dose escalation in combination with fulvestrant
DRUG: ETX-636 dose expansion in combination with fulvestrant

Sponsor

Ensem Therapeutics